|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Consistently, loss of PRMT6 expression aggravated liver tumorigenesis in a chemical-induced HCC PRMT6 knockout (PRMT6<sup>-/-</sup>) mouse model.
|
30332648 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Herein we aimed to uncover the potential oncogenic role of PRMT6 in prostate carcinogenesis.
|
27323813 |
2016 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of tumor suppressor PCDH7 in the PRMT6-KO GC cells elevated cell migration and invasion.
|
30508037 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Stable PRMT6 knockdown in PC-3 cells attenuated malignant phenotype, increasing apoptosis and decreasing cell viability, migration and invasion.
|
27323813 |
2016 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, this suppression of migration and invasion by PRMT6 overexpression was significantly rescued by specific knock-down of TSP-1.
|
23380452 |
2013 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
DNMT1 and PRMT6 decreased expression of the tumor suppressor genes Cdkn1a (P21) and Cdkn1b (p27) via DNA methylation and histone H3R2 dimethylation-mediated repression of transcription, respectively.
|
31154022 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, we showed as a proof-of-concept the therapeutic potential of using 2-deoxyglucose (2DG), a glycolysis inhibitor, to reverse tumorigenicity and sorafenib resistance mediated by PRMT6 deficiency in HCC.
|
31469916 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Significant association of PRMT6 hypomethylation with colorectal cancer.
|
29927001 |
2018 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, there is no clear evidence regarding the prognostic value of abnormal PRMT6 expression in colorectal cancer or the effect of PRMT6 regulation on CRC cells.
|
29507670 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Silencing of PRMT6 promoted the tumor-initiating, metastasis, and therapy resistance potential of HCC cell lines and patient-derived organoids.
|
30332648 |
2018 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our work describes a critical repressive function for PRMT6 in maintenance of HCC cells by regulating RAS binding and MEK/ERK signaling via methylation of CRAF on arginine 100.
|
30332648 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The protein arginine N-methyltransferase 6 (PRMT6) is overexpressed in a variety of different cancer types and plays a role in human immunodeficiency virus (HIV) infections.
|
29410016 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
Significant association of PRMT6 hypomethylation with colorectal cancer.
|
29927001 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, there is no clear evidence regarding the prognostic value of abnormal PRMT6 expression in colorectal cancer or the effect of PRMT6 regulation on CRC cells.
|
29507670 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |